Explore terminated, suspended, and withdrawn clinical trials
Search the ClinicalTrials.gov-derived stopped-trial dataset by sponsor, phase, disease area, intervention, status, and classified stop reason.
23,539 results
Sel
Trial
Title
Phase
Disease area
Condition
Intervention
Status
Reason
Why stopped
Last updated
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
GlaxoSmithKline
Phase I
Other
Cough
Camlipixant
SUSPENDED
OTHER/UNKNOWN
The study has been suspended given the recent decision to cease further development of camlipixant in RCC based on Phase 3 program results.
2026-07-24
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase I
Oncology
Multiple Myeloma
Mirdametinib
SUSPENDED
OPERATIONAL
Administrative hold pending non-safety related changes to the study design.
2026-07-24
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NeuroTrauma Sciences, LLC
Phase I
Cardiovascular
Acute Ischemic Stroke
NTS-104 TRIS
TERMINATED
OTHER/UNKNOWN
a second generation product was found to be more relevant for development
2026-07-24
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase I
Oncology
Non-Small Cell Lung Cancer
Montanide (Registered Trademark) ISA-51 VG Adjuvant
SUSPENDED
OPERATIONAL
Revisions to eligibility/design being made prior to enrollment of first participants.
2026-07-24
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Spectrum Pharmaceuticals, Inc
Phase III
Other
NSCLC
Poziotinib
SUSPENDED
OTHER/UNKNOWN
The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.
2026-07-24
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
University of Maryland, Baltimore
Phase IV
Immunology & Autoimmune
Substance Use Disorders
Oritavancin
TERMINATED
OTHER/UNKNOWN
The study was not able to enroll adequate participants within predetermined timelines
2026-07-24
A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression
Massachusetts General Hospital
Phase IV
Psychiatry & Mental Health
Bipolar Disorder
N-acetylcysteine
WITHDRAWN
OPERATIONAL
Study did not receive funding and was never carried out.
2026-07-24
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
iOmx Therapeutics AG
Phase I
Oncology
Solid Tumor
OMX-0407
TERMINATED
OTHER/UNKNOWN
Study terminated as part of strategic considerations and not based on safety concerns.
2026-07-24
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase II
Oncology
Locally Advanced Malignant Solid Neoplasm
Biopsy Procedure
SUSPENDED
OPERATIONAL
Other - study has reached accrual goal for analysis
2026-07-24
Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)
National Institute of Allergy and Infectious Diseases (NIAID)
Phase I
Infectious Disease
Malaria
PfSPZ Vaccine
SUSPENDED
REGULATORY
The study remains on hold due to a funding issue after it's been lifted by the FDA.
2026-07-24
A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z
AstraZeneca
Phase I
Oncology
Advanced Solid Tumours
Ceralasertib
TERMINATED
OTHER/UNKNOWN
The study terminated because the clinical development programme for Ceralasertib has been discontinued.
2026-07-24
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Phase I
Oncology
Recurrent Acute Myeloid Leukemia
Biospecimen Collection
SUSPENDED
EFFICACY/FUTILITY
Pending Interim Analysis
2026-07-24
A Dose Finding Study to Treat Bone Tumor(s)
QSAM Therapeutics, Inc.
Phase I
Oncology
Bone Cancer
153-Sm-DOTMP (Samarium-153-DOTMP)
TERMINATED
OTHER/UNKNOWN
Change in development program indication
2026-07-23
Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
University of Minnesota
Early Phase I
Hematology (non-onc)
Hemophilia
1%Tranexamic acid with standard local
WITHDRAWN
OTHER/UNKNOWN
Lack of Participants
2026-07-23
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase I
Oncology
Advanced Cancer
Fosifloxuridine Nafalbenamide
TERMINATED
OTHER/UNKNOWN
The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.
2026-07-23
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Evopoint Biosciences Inc.
Phase I
Oncology
Carcinoma
XNW5004
TERMINATED
OPERATIONAL
Strategic decision by Sponsor.
2026-07-23
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
Shanghai Changzheng Hospital
Early Phase I
Oncology
Renal Cell Carcinoma
anti-CD70-CAR-T cells
SUSPENDED
OTHER/UNKNOWN
Modifications to the trial design
2026-07-23
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
Phase I
Oncology
Breast Cancer, Breast Neoplasms
GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells.
TERMINATED
OPERATIONAL
The Sponsor has made a strategic decision to stop the development of GEN1047.
2026-07-23
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
Genfit
Phase II
Gastroenterology & Hepatology
Acute-On-Chronic Liver Failure
VS-01 on top of SOC
TERMINATED
OPERATIONAL
Sponsor Decision
2026-07-23
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Alessandro D'Agnolo
Phase II
Oncology
Prostatic Neoplasms
18F-PSMA
TERMINATED
OPERATIONAL
Funding ceased before all specimen collection and analysis could be completed
2026-07-22
Retreatment With CTL019/CTL119
University of Pennsylvania
Phase I
Oncology
Lymphoma, B-Cell
CD19 redirected autologous T cells (CTL019 or CTL119 cells)
WITHDRAWN
OTHER/UNKNOWN
Lack of Eligible Subjects
2026-07-22
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
University of Utah
Phase II
Oncology
Non-Small Cell Lung Cancer Metastatic
Durvalumab
TERMINATED
OPERATIONAL
Closed due to slow accrual
2026-07-22
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Phase I
Oncology
Advanced Malignant Solid Neoplasm
Everolimus
TERMINATED
OTHER/UNKNOWN
\<75% participation
2026-07-22
Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response
Chang Gung Memorial Hospital
Unknown
Gastroenterology & Hepatology
Liver Fibrosis
Ursodeoxycholic Acid (URSO)
TERMINATED
OPERATIONAL
Slow recruitment and exhaustion of available study funding.
2026-07-22
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
Candid Therapeutics
Phase I
Other
IgE-Mediated Hypersensitivity
Cizutamig
WITHDRAWN
OPERATIONAL
Sponsor decision
2026-07-22
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
University of Colorado, Denver
Phase II
Oncology
Microsatellite Stable Metastatic Colorectal Cancer
Evorpacept (ALX148)
TERMINATED
SAFETY
Accrual was terminated due to safety concerns
2026-07-22
CRF2 Agonist for the Treatment of Worsening Heart Failure
Corteria Pharmaceuticals
Phase II
Cardiovascular
Worsening Heart Failure
COR-1167
SUSPENDED
OPERATIONAL
The DSMB recommended pausing the enrollment to give time to the Executive Committee to revise the eligibility criteria to exclude patients who may be in impending cardiogenic shock or in other ways too ill to safely participate in the trial.
2026-07-22
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Celgene
Phase II
Oncology
Carcinoma, Non-Small-Cell Lung
CC-486
TERMINATED
OTHER/UNKNOWN
—
2026-07-22
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Early Phase I
Oncology
Multiple Myeloma
ESO-T01 Injection
SUSPENDED
OTHER/UNKNOWN
The collaborator EsoBiotec was acquired by AstraZeneca.
2026-07-22
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Phase II
Oncology
Castration-Resistant Prostate Carcinoma
Abiraterone Acetate/Niraparib
TERMINATED
OPERATIONAL
Sponsor decided to close due to slow accrual and lack of efficacy
2026-07-22
Silver Nitrate vs. Triamcinolone for Treatment of Hypergranulation Tissue
Francesco Egro
Phase II
Other
Wound Healing
Silver Nitrate
WITHDRAWN
OPERATIONAL
No subjects recruited at this time
2026-07-22
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Alexion Pharmaceuticals, Inc.
Phase III
Cardiovascular
Chronic Kidney Disease
Placebo
TERMINATED
EFFICACY/FUTILITY
The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.
2026-07-22
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Amryt Pharma
Phase III
Other
Generalized Lipodystrophy
Metreleptin
TERMINATED
OTHER/UNKNOWN
This clinical trial was closed early due to no longer being a requirement to the European Medicines Agency.
2026-07-22
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy
Mayo Clinic
Phase I
Oncology
Prostate Cancer
Ad5-CMV-NIS
TERMINATED
OPERATIONAL
closed early due to poor accrual
2026-07-22
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen, a wholly owned subsidiary of Pfizer
Phase I
Oncology
Cervical Cancer
Tisotumab Vedotin
TERMINATED
OPERATIONAL
Sponsor has decided to stop the trial based on strategic decisions
2026-07-22
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
Phase I
Gastroenterology & Hepatology
T-Cell Non-Hodgkin Lymphoma
WU-CART-007
SUSPENDED
OTHER/UNKNOWN
Drugs/Equipment Unavailable
2026-07-21
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase I
Oncology
Acute Myeloid Leukemia
Decitabine
SUSPENDED
OPERATIONAL
PI Request
2026-07-21
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Sol-Gel Technologies, Ltd.
Phase II
Oncology
Recurrent Basal Cell Carcinoma
Patidegib Topical Gel, 2%
TERMINATED
OTHER/UNKNOWN
Terminated early due to low blinded event rate
2026-07-21
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
Phase I
Gastroenterology & Hepatology
Gastrointestinal Cancer
BI 765049
TERMINATED
OPERATIONAL
Sponsor decision
2026-07-21
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
Phase I
Oncology
Breast Cancer
Elacestrant
TERMINATED
OPERATIONAL
Sponsor decision to discontinue onapristone development.
2026-07-21
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Phase II
Oncology
Non-small Cell Lung Cancer
Alectinib
TERMINATED
OPERATIONAL
Low recruitment rate
2026-07-21
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
M.D. Anderson Cancer Center
Phase II
Oncology
Locally Advanced Angiosarcoma
Quality-of-Life Assessment
TERMINATED
OPERATIONAL
PI request, \<75% participation
2026-07-21
Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA
Shanghai Junshi Bioscience Co., Ltd.
Phase II
Immunology & Autoimmune
Non-radiographic Axial Spondyloarthritis
JS005
TERMINATED
OTHER/UNKNOWN
Company research and development strategy adjustment, decided to study temporarily
2026-07-21
Gadopiclenol in Contrast Enhanced MRI of the Prostate
Columbia University
Phase IV
Oncology
Prostate Cancer
Gadopiclenol
SUSPENDED
OTHER/UNKNOWN
The study is being transferred to another institution
2026-07-20
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase II
Other
Progressive Glioblastoma
Biopsy Procedure
SUSPENDED
OTHER/UNKNOWN
Scheduled Interim Monitoring
2026-07-20
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Celgene
Phase I
Other
Healthy Volunteers
BMS-986365
TERMINATED
OTHER/UNKNOWN
Business objectives have changed
2026-07-20
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
Phase I
Oncology
Diffuse Large B-Cell Lymphoma
Loncastuximab Tesirine
TERMINATED
OTHER/UNKNOWN
This decision to close the study was made following interactions with regulatory authorities and in consideration of the challenges associated with this patient population. No safety information contributed to this decision.
2026-07-20
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
Syed Hamza Mufarrih
Phase IV
Cardiovascular
Heart Failure
Ferric Carboxymaltose
TERMINATED
OTHER/UNKNOWN
Post-discharge low follow-up (\<50%) rates.
2026-07-20
Geisinger Antibiotic Allergy Pilot Program: Assess and Address
Geisinger Clinic
Early Phase I
Other
Penicillin Allergy
Amoxicillin
TERMINATED
OTHER/UNKNOWN
PI does not wish to proceed due to a different clinical decision tool becoming available
2026-07-20
What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery
University of Alberta
Unknown
Oncology
Breast Cancer
TMP-SMX DS
TERMINATED
OPERATIONAL
Logistical Issues
2026-07-20
Tip: scroll vertically inside the table; use horizontal scroll to view all columns.
NCT07684586
A Study to Investigate the Difference In Blood Levels of Camlipixant Between Different Camlipixant Formulation Prototypes
GlaxoSmithKline
Last updated
2026-07-24
Why stopped
The study has been suspended given the recent decision to cease further development of camlipixant in RCC based on Phase 3 program results.
NCT06876142
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma
National Cancer Institute (NCI)
Last updated
2026-07-24
Why stopped
Administrative hold pending non-safety related changes to the study design.
NCT05547438
Single Ascending Dose Safety and Tolerability of NTS-104 Healthy Adults
NeuroTrauma Sciences, LLC
Last updated
2026-07-24
Why stopped
a second generation product was found to be more relevant for development
NCT05642195
Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Last updated
2026-07-24
Why stopped
Revisions to eligibility/design being made prior to enrollment of first participants.
NCT05378763
A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations
Spectrum Pharmaceuticals, Inc
Last updated
2026-07-24
Why stopped
The study has not enrolled any patients. The study design is under discussion and will likely be redesigned in consultation with the FDA.
NCT05521880
Anchoring Sequential Intermittent Long Acting Antimicrobials With Medication for Opioid Use Disorder (MOUD) for Invasive Infections Related to Opioid Use
University of Maryland, Baltimore
Last updated
2026-07-24
Why stopped
The study was not able to enroll adequate participants within predetermined timelines
NCT02719392
A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression
Massachusetts General Hospital
Last updated
2026-07-24
Why stopped
Study did not receive funding and was never carried out.
NCT05826600
A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically
iOmx Therapeutics AG
Last updated
2026-07-24
Why stopped
Study terminated as part of strategic considerations and not based on safety concerns.
NCT05554380
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Last updated
2026-07-24
Why stopped
Other - study has reached accrual goal for analysis
NCT05652504
Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1)
National Institute of Allergy and Infectious Diseases (NIAID)
Last updated
2026-07-24
Why stopped
The study remains on hold due to a funding issue after it's been lifted by the FDA.
Last updated
2026-07-24
Why stopped
The study terminated because the clinical development programme for Ceralasertib has been discontinued.
NCT07025564
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
City of Hope Medical Center
Last updated
2026-07-24
Why stopped
Pending Interim Analysis
Last updated
2026-07-23
Why stopped
Change in development program indication
NCT06345833
Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
University of Minnesota
Last updated
2026-07-23
Why stopped
Lack of Participants
NCT05714553
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Last updated
2026-07-23
Why stopped
The NuTide:303 study was terminated at NuCana's discretion following refinement of the NUC-3373 development strategy.
NCT06022757
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
Evopoint Biosciences Inc.
Last updated
2026-07-23
Why stopped
Strategic decision by Sponsor.
NCT06586658
Anti-CD70-CAR-T Cell Injection for the Treatment of Locally Advanced or Relapsed/Metastatic CD70+ Inoperable Renal Cells
Shanghai Changzheng Hospital
Last updated
2026-07-23
Why stopped
Modifications to the trial design
Last updated
2026-07-23
Why stopped
The Sponsor has made a strategic decision to stop the development of GEN1047.
NCT05900050
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
Genfit
Last updated
2026-07-23
Why stopped
Sponsor Decision
NCT04461509
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Alessandro D'Agnolo
Last updated
2026-07-22
Why stopped
Funding ceased before all specimen collection and analysis could be completed
Last updated
2026-07-22
Why stopped
Lack of Eligible Subjects
NCT04163432
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
University of Utah
Last updated
2026-07-22
Why stopped
Closed due to slow accrual
NCT03065387
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
M.D. Anderson Cancer Center
Last updated
2026-07-22
Why stopped
\<75% participation
NCT07102979
Remedial Mechanism of Simvastatin and Ursodeoxycholic Acid in Liver Cirrhosis: Crosstalk of Bile Secretion, Gut Microbiome, and Host Immune Response
Chang Gung Memorial Hospital
Last updated
2026-07-22
Why stopped
Slow recruitment and exhaustion of available study funding.
Last updated
2026-07-22
Why stopped
Sponsor decision
NCT05167409
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
University of Colorado, Denver
Last updated
2026-07-22
Why stopped
Accrual was terminated due to safety concerns
Last updated
2026-07-22
Why stopped
The DSMB recommended pausing the enrollment to give time to the Executive Committee to revise the eligibility criteria to exclude patients who may be in impending cardiogenic shock or in other ways too ill to safely participate in the trial.
NCT02546986
Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer
Celgene
Last updated
2026-07-22
Why stopped
—
NCT06691685
A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last updated
2026-07-22
Why stopped
The collaborator EsoBiotec was acquired by AstraZeneca.
NCT05689021
CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations
Mayo Clinic
Last updated
2026-07-22
Why stopped
Sponsor decided to close due to slow accrual and lack of efficacy
Last updated
2026-07-22
Why stopped
No subjects recruited at this time
NCT05746559
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Alexion Pharmaceuticals, Inc.
Last updated
2026-07-22
Why stopped
The ALXN1210-CSA-AKI-318 trial was discontinued on 29-Apr-2026 due to lack of efficacy in this overall study universe / patient population.
NCT06502990
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Amryt Pharma
Last updated
2026-07-22
Why stopped
This clinical trial was closed early due to no longer being a requirement to the European Medicines Agency.
NCT00788307
Gene Therapy and Radioactive Iodine in Treating Patients With Locally Recurrent Prostate Cancer That Did Not Respond to Radiation Therapy
Mayo Clinic
Last updated
2026-07-22
Why stopped
closed early due to poor accrual
NCT03786081
Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer
Seagen, a wholly owned subsidiary of Pfizer
Last updated
2026-07-22
Why stopped
Sponsor has decided to stop the trial based on strategic decisions
NCT05377827
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
Last updated
2026-07-21
Why stopped
Drugs/Equipment Unavailable
NCT03661307
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Last updated
2026-07-21
Why stopped
PI Request
NCT04155190
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Sol-Gel Technologies, Ltd.
Last updated
2026-07-21
Why stopped
Terminated early due to low blinded event rate
NCT06091930
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
Boehringer Ingelheim
Last updated
2026-07-21
Why stopped
Sponsor decision
NCT05618613
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
Context Therapeutics Inc.
Last updated
2026-07-21
Why stopped
Sponsor decision to discontinue onapristone development.
NCT03445000
ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
Last updated
2026-07-21
Why stopped
Low recruitment rate
NCT05026736
Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study
M.D. Anderson Cancer Center
Last updated
2026-07-21
Why stopped
PI request, \<75% participation
NCT05242588
Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active Nr-axSpA
Shanghai Junshi Bioscience Co., Ltd.
Last updated
2026-07-21
Why stopped
Company research and development strategy adjustment, decided to study temporarily
Last updated
2026-07-20
Why stopped
The study is being transferred to another institution
NCT06325683
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Last updated
2026-07-20
Why stopped
Scheduled Interim Monitoring
NCT07242781
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Celgene
Last updated
2026-07-20
Why stopped
Business objectives have changed
NCT05660395
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
ADC Therapeutics S.A.
Last updated
2026-07-20
Why stopped
This decision to close the study was made following interactions with regulatory authorities and in consideration of the challenges associated with this patient population. No safety information contributed to this decision.
NCT07053475
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
Syed Hamza Mufarrih
Last updated
2026-07-20
Why stopped
Post-discharge low follow-up (\<50%) rates.
Last updated
2026-07-20
Why stopped
PI does not wish to proceed due to a different clinical decision tool becoming available
NCT05823467
What is Optimal Post-operative Prophylactic Therapy in Irradiated Breasts Undergoing Repeat Surgery
University of Alberta
Last updated
2026-07-20
Why stopped
Logistical Issues
Tip: the mobile list is virtualized; scroll inside the results area.